Cancer genome analyses have revealed that the enzymes involved in epigenetic gene regulation are frequently deregulated in cancer. Here we describe the enzymes that control the epigenetic state of the cell, how they are affected in cancer and how this knowledge can be exploited to treat cancer with a new arsenal of selective therapies.
Introduction
Epigenetics is the study of heritable changes in gene expression that do not involve alterations of the DNA sequence (Kelly et al., 2010) . Many of these changes involve alterations of the chromatin: the state in which DNA is stored inside the cell. Eukaryotic DNA is packaged in nucleosomes, which comprise octamers of four core histone proteins (H2A, H2B, H3 and H4) around which 147 bp of DNA is wrapped. Accessibility of DNA is determined by repositioning and restructuring of the nucleosomes by ATP-dependent chromatin remodellers, through covalent modifications of the histones by histone-modifying enzymes and through modifications on the DNA itself by DNA-modifying enzymes. There is substantial interplay between the many epigenetic regulators, which together control transcription. Globally, chromatin can be in two states, the open state (euchromatin) in which DNA is available for transcription and a closed state (heterochromatin) in which the DNA is tightly packed, precluding its transcription.
In addition to alterations in the primary DNA sequence, cancers often harbour multiple epigenetic alterations, here referred to as epimutations, which also affect key regulatory signalling pathways that are required for normal cellular physiology. Moreover, epimutations can outnumber genetic abnormalities and often occur early in cancer development (Esteller et al., 1999; Schuebel et al., 2007; Chen et al., 2009) . Such epimutated genes are often tumour-suppressor genes (TSGs), including the DNA-repair proteins MutL homologue-1 (MLH1) and BRCA1, the INK4A-ARF locus-encoded cell-cycle inhibitors (CDKN2A and CDKN2B) and von Hippel-Lindau (VHL), which controls cell survival and angiogenesis. Many epigenetic regulators, including those responsible for silencing of the above mentioned TSGs, are deregulated in cancer.
Recent cancer genome analyses have identified an impressive and still increasing number of epigenetic enzymes that are deregulated in many types of cancers, establishing a direct link between cancer genetics and cancer epigenetics. Recurrent loss-of-function and gainof-function mutations affecting nucleosome-remodelling complexes, histone modifiers and DNA-modifying enzymes occur in many cancers (Table 1 and discussed below), clearly demonstrating that at least three major epigenetic mechanisms are deregulated in cancer. Epigenetic enzymes are attractive drug targets because of the reversible nature of epigenetic modifications. The recognition that epigenetic enzymes are frequently deregulated in cancer has fuelled the development of inhibitors of these, referred to here as 'epigenetic drugs'. Epigenetic drugs can be divided into two classes. The first class consists of non-selective agents, including the clinically used inhibitors of DNA methyltransferases (DNMTi) and histone deacetylases (HDACi), and the more recently discovered inhibitors of EZH2 and LSD1. Of this class, both DNMTis and HDACis are approved for treatment of cancer. The second class consists of more selective inhibitors, including those targeting JAK2, G9a/GLP and DOT1L. In this review, we will discuss those epigenetic enzymes deregulated in cancer and the feasibility to target these for cancer therapy.
DNA-modifying enzymes
DNMTs convert the cytosine residues of CpG dinucleotides into 5-methylcytosine, which can be further converted into 5-hydroxymethyl-2 0 -deoxycytidine by the Ten-Eleven-Translocation (TET) family (Tahiliani et al., 2009; Ito et al., 2010) . CpG dinucleotides are highly enriched in small genomic regions, known as CpG islands, which frequently coincide with promoter regions. Most CpG dinucleotides are methylated except those found in the promoter-located CpG islands, Targeting the epigenome for cancer treatment E-J Geutjes et al excluding imprinted loci and the inactive X-chromosome. While the function of 5-hydroxylmethylation is unclear, hyper-methylation of DNA at CpG islands inhibits transcription by preventing recognition by transcriptional activators and by serving as a recognition signal for specific chromatin interactors, which in turn recruit co-repressors and nucleosome remodellers. Of the five DNMTs only DNMT1, 3A and 3B have catalytic activity. DNMT3A and DNMT3B can methylate previously unmethylated sites, which are then copied to daughter cells by DNMT1 during replication. The cancer epigenome is marked by genome-wide DNA hypo-methylation and site-specific DNA hypermethylation. DNA hypo-methylation promotes genomic instability, activates tumour-promoting genes and leads to loss of imprinting, whereas DNA hyper-methylation blocks transcription factor-binding sites and silences TSGs. DNA-modifying enzymes are overexpressed, mislocalized or mutated in cancer. The level and activity of DNMTs appear to be modestly elevated in various cancer types, which could lead to aberrant promoter hyper-methylation, as DNMT3B overexpression in normal mouse colon induces de novo DNA methylation of TSGs (Ting et al., 2006; Steine et al., 2011) . DNMTs can also be mislocalized in cancer, resulting in aberrant hyper-methylation. For example, the leukaemiapromoting PML-RARa fusion protein and several Polycomb Group (PcG) proteins induce aberrant promoter hyper-methylation by recruiting DNMTs to target promoters of TSGs (Di Croce et al., 2002; Vire et al., 2006) . Highly recurrent heterozygous mutations in DNMT3A, yielding a partially defective enzyme, have recently been discovered in acute myeloid leukaemia (AML) and myelodysplastic syndrome, and are associated with poor clinical outcome (Ley et al., 2010; Yan et al., 2011) . These mutations were proposed to compromise the binding of DNMT3A to chromatin or to proteins associating with DNMT3A. Bi-and monoallelic loss-of-function mutations in TET2 were identified in many haematological malignancies, in association with global 5hmC depletion (Delhommeau et al., 2009; Langemeijer et al., 2009; Ko et al., 2010) . Biallelic Tet2 loss in the mouse impairs hematopoietic differentiation and induces myeloid transformation. Tet2 haploinsufficiency confers increased self-renewal and myeloproliferation, suggesting that TET2 functions (Bagchi et al., 2007; Fujita et al., 2008; Mulero-Navarro and Esteller, 2008) Abbreviations: AML, acute myeloid leukaemia; CML, chronic myeloid leukaemia; CTCL, cutaneous T-cell lymphoma; DLBCL, diffuse large B-cell lymphoma; LOH, loss-of-heterozygosity; MDS, myelodysplastic syndrome; MF, myelofibrosis; MM, multiple myeloma.
Targeting the epigenome for cancer treatment E-J Geutjes et al as a haploinsufficient TSG (Moran-Crusio et al., 2011; Quivoron et al., 2011) . DNMTis such as the azanucleosides azacitidine (5-azacytidine) and decitabine (5-aza 0 2-deoxycytidine) induce differentiation and/or apoptosis. At low doses, azanucleosides sequester and degrade DNMTs after incorporation into DNA, leading to global DNA demethylation and consequent reactivation of promoter hyper-methylated genes, including aberrantly silenced TSGs. However, azanucleosides also induce gene expression changes independent of active DNA demethylation, for example by inducing degradation of the histone methyltransferase G9a, which may also contribute to their clinical effectiveness (Gius et al., 2004; Wozniak et al., 2007) . Azacitidine and decitabine are clinically used in high-risk myelodysplastic syndrome and have demonstrated clinical efficacy in treatment of AML (reviewed by Kelly et al., 2010) (Table 2 ). The many clinical trials testing DNMTis have failed to find other DNMTi-responsive cancers, in particular solid tumours (reviewed by Quintas-Cardama et al., 2010) . Only some therapeutic benefit of DNMTi treatment was observed in chronic myeloid leukaemia (Aribi et al., 2007; Wijermans et al., 2008) . Besides azacitidine and decitabine, there are many new DNMTis that are all capable of reverting aberrant promoter hyper-methylation (Figure 1 ). Azanucleosides S-110 and zebularine, and the quinoline-based DNMTi SGI-1027, are more stable than azacitidine and decitabine, and show activity in cancer cell lines and mouse models of cancer (Cheng et al., 2003; Yoo et al., 2007; Datta et al., 2009) . Isoformspecific inhibitors of DNMT1 (RG108) and DNMT3B (nanaomycin-A) have been developed, but only nanaomycin-A appears to have potent antiproliferative effects (Brueckner et al., 2005; Kuck et al., 2010) .
Histone-modifying enzymes
Histones can be modified dynamically by multiple chemical groups, including acetyl, methyl, phosphoryl and ubiquityl groups. These modifications serve to open or close the chromatin structure, and promote or occlude proteins from binding to the chromatin. Broadly, we can discriminate three classes of histoneinteracting proteins. The writers place histone modifications, which can subsequently be removed by erasers. Finally, readers bind to chromatin through specific domains that read the histone modifications and can deliver nucleosome, histone or DNA-modifying enzymes.
Lysine acetylases. Lysine acetyltransferases (KATs) acetylate the lysine residues of histone proteins and non-histone proteins, including p53 and E2F1. They can be divided into three classes, namely GCN5/PCAF, p300/CBP and MYST/TIP60. The GCN5/PCAF and p300/CBP groups mainly function as coactivators for various transcription factors, but the MYST family also has roles in other nuclear processes.
The structural and functional homologues p300/ KAT3A and CBP/KAT3B, and the MYST family members TIP60/KAT5 and MYST3/MOZ/KAT6A, are frequently mutated or dysregulated in cancer. Monoallelic mutation of CBP causes Rubinstein-Taybi syndrome, a severe developmental disorder that predisposes to cancer development (Petrij et al., 1995) . Recently, frequent genomic deletions and mutations of CBP, all concentrated in the catalytic domain, were detected in B-cell non-Hodgkin's lymphoma, bladder cancer and tumours of patients with relapsed lymphoblastic leukaemia (Gui et al., 2011; Mullighan et al., 2011; Pasqualucci et al., 2011) . In B-cell non-Hodgkin's lymphomas, the CBP mutants were unable to acetylate p53, thereby compromising its transcriptional activity, and BCL6, blocking its transcriptional repressor function. Mice with monoallelic ablation of Cbp develop highly penetrant leukaemia's, demonstrating that CBP has tumour-suppressive activity (Kung et al., 2000) . CBP and p300 are also dysregulated by viral oncoproteins and translocations. The viral oncoproteins E1A and Large T misregulate p300 and CBP to activate cell-cycle progression-promoting genes by histone acetylation, leading thereby contributing to cellular transformation (Eckner et al., 1994; Ferrari et al., 2008) . In leukemia, p300 and CBP are commonly fused to the histone methyltransferase Mixed Lineage Leukemia (MLL) (see also lysine methyltransferases (KMTs)) and two other KATs, MYST3 or MYST4/MORF/ KAT6B. The MLL-CBP fusion protein induces myelodysplastic syndrome in mice (Lavau et al., 2000) .
In contrast to CBP and p300, MYST3 appears to have oncogenic properties. Recurrent amplifications of MYST3 have recently been identified in medulloblastoma. (Northcott et al., 2009) . Unlike MLL-CBP and MLL-MYST4, the MYST3-CBP fusion protein functions as a transcriptional repressor by blocking hematopoietic stem cell differentiation by inhibition of RUNX1-dependent transcription (Kitabayashi et al., 2001a) . TIP60 may function as a haploinsufficient TSG as monoallelic losses of TIP60 have been detected in lymphomas, breast carcinomas, and head and neck cancer (Gorrini et al., 2007) . Monoallelic loss of Tip60 impairs the Myc-induced DNA-damage response and is sufficient to counteract Myc-induced lymphomagenesis in mouse experimental models (Gorrini et al., 2007) . In addition, recurrent mutations in the transformation/ transcription domain-associated protein (TRRAP), encoding a cofactor of TIP60-containing complexes, were recently described in melanoma, suggesting that inhibition of TIP60 complexes contributes to carcinogenesis (Wei et al., 2011) . Apart from the classical KATs, amplified in breast cancer-1 (AIB1) also has intrinsic KAT activity and associates with CBP and p300 (Chen et al., 1997) . AIB1 is involved in many signalling pathways important for oncogenesis of breast cancer, for example by functioning as a co-activator for oestrogen and progesterone signalling (Lahusen et al., 2009) . Amplification of AIB1 frequently occurs in breast cancer and ablation of Aib1 in the mouse leads to B-cell lymphoma (Anzick et al., 1997; Coste et al., 2006) .
Inhibitors of p300 and CBP, including garcinol, curcumin and anacardic acid, were reported to kill cancer cells but not non-malignant cells (Balasubrama- (Figure 2 ). In addition, a novel small-molecule inhibitor of p300 substantially reduced growth of patient-derived oral squamous cell carcinoma xenografts in mice, in which, unlike most cancers, histones are highly hyper-acetylated (Arif et al., 2010) . Given the tumour-suppressive role of CBP, p300 is likely the relevant target of these inhibitors. Inhibitors of p300 may be particularly effective in cancers in which p300 is translocated or dysregyulated. A recent study found that inhibition of p300 impaired leukemogenesis in mouse models expressing the oncogenic translocation product AML1-ETO by blocking the acetylation of AML1-ETO by p300 (Zuber et al., 2011) . JQ1 also induced senescence in mouse models of multiple myeloma by downregulation of Myc, which was regulated by bromo domain-containing proteins (Delmore et al., 2011) .
Lysine deacetylases. HDACs remove acetyl groups from lysine residues on histones and non-histone proteins, and are considered to be transcriptional repressors. Eighteen HDACs have been identified that are grouped into four classes. Class-I, II and IV HDACs are Zn 2 þ -dependent enzymes, whereas class-III HDACs, referred to as sirtuins, use NAD þ as cofactor. The HDAC isoforms function in many cellular processes and have distinct gene expression patterns, cellular localization and function (Haberland et al., 2009b) . HDACs commonly interact with DNA-binding proteins, such as transcription factors, which in turn target HDACs to specific DNA sequences. Some HDACs reside in multiprotein complexes, which associate with specific genomic loci. For example, HDAC1 and 2 are constituents of the NuRD, SIN3A and Co-REST repressor complexes, and HDAC3 is found within the N-COR and SMRT repressor complexes.
The cancer epigenome is hallmarked by a global reduction of lysine hypo-acetylation and many HDACs are altered in expression or mislocalized in cancer. Class-I HDACs (1, 2, 3 and 8) are overexpressed in many tumours and their increased expression correlates with poor outcome in some tumours, suggesting that these HDACs are oncogenes (Weichert, 2009 ). The tumour growth of transformed fibroblasts can be completely blocked by genetic deletion of both Hdac1 and 2 (Haberland et al., 2009a) . Transgenic expression of a catalytically inactive Hdac2 in tumour-prone Apc þ /À mice reduced intestinal tumour incidence (Zimmermann et al., 2007) . Inactivation of HDAC8 induces differentiation of neuroblastoma cells (Oehme et al., 2009) . The role of the other Zn 2 þ -dependent HDACs in carcinogenesis has not been explored thoroughly, with the exception of HDAC6. HDAC6 is overexpressed at the protein level in breast cancer and loss of Hdac6 cooperates with oncogenic Ras in mouse fibroblasts (Saji et al., 2005; Lee et al., 2008) . Similar to DNMTs, HDACs can be recruited by oncogenic transcription factors. BCL6, PML-RARa, PLZF-RARa and AML-ETO can recruit HDAC-containing repressor complexes to repress specific target genes (Bolden et al., 2006) .
HDACis can restore global lysine acetylation levels in cancer cells and induce the de-acetylation of many non-histone proteins (Choudhary et al., 2009) . However, the activities of HDACis may also be independent of HDAC inhibition as they have non-HDAC targets (Bantscheff et al., 2011) . HDACis induce apoptosis, differentiation and cell-cycle arrest in cancer cells, and have anti-angiogenic, anti-invasive and immunomodulatory properties in vivo (Lane and Chabner, 2009) . Current HDACis for cancer therapy are structurally very diverse agents that target Zn 2 þ -dependent HDACs and have marked differences in specificity and potency (Bradner et al., 2010; Bantscheff et al., 2011) . The HDACis vorinostat (SAHA) and romidepsin (FK228) are clinically used in cutaneous T-cell lymphomas (Mann et al., 2007; Whittaker et al., 2010) (Table 2 and Figure 2 ). Many other HDACis are in clinical development, with the following being tested in phase-2 clinical trials: belinostat (PXD-101), panobinostat (LBH589), SB939, givinostat (ITF2357), entinostat (SNDX-275/MS-275) and mocetinostat (MGCD0103) (Wagner et al., 2010) (Table 2 and Figure 2 ). Most clinical trials testing HDACis found variable therapeutic benefit of HDACis in cancers other than T-cell lymphomas (reviewed by Wagner et al., 2010) . Ongoing phase-3 clinical trials are testing the clinical efficacy of vorinostat in advanced mesothelioma, and panobinostat in Hodgkin's lymphoma and refractory chronic myeloid leukaemia. Isoform-specific HDACis targeting oncogenic HDACs have been developed (Figure 2) . Selective inhibitors of HDAC6 or HDAC8 induce tumour cell death by targeting pathways regulated by these HDACs (Hideshima et al., 2005; Balasubramanian et al., 2008; Namdar et al., 2010) . HDACis can also be combined with DNMTis, given their ability to more effectively reactivate those TSGs, including CDKN2A and MLH1, that are silenced in association with histone hypoacetylation and promoter hyper-methylation (Cameron et al., 1999) . Moreover, this combination synergizes in induction of cancer cell death in vitro and appears to have enhanced clinical efficacy in early clinical studies (Zhu et al., 2001; Garcia-Manero et al., 2006; Gore et al., 2006; Blum et al., 2007; Braiteh et al., 2008; Voso et al., 2009; Stathis et al., 2011) .
Lysine methylases. Histone lysine methylation can induce gene activation or repression, depending on the lysine involved. In general, methylation of H3K4, H3K36 and H3K79 is associated with gene activation, whereas methylation of H3K9, H3K27 and H4K20 is characteristic of repressed chromatin. KMTs methylate the lysine residues of histone and non-histone proteins, and all have a SET domain or a structurally related PR (PRDI-BF1 and RIZ homology) domain, which confers the catalytic activity, with the exception of DOT1L/ KMT4. Some KMTs are part of major transcriptionregulatory protein complexes. The MLL/KMT2-family members reside in protein complexes that regulate the initiation or elongation of transcription, whereas EZH2/ KMT6 is a core subunit of the Polycomb protein complex-2 (PRC2), which controls the cell lineage by repressing HOX genes.
Many KMTs are mutated, translocated or overexpressed in cancer. The KMT1 family consists of SUV39H1/KMT1A, SUV39H2/KMT1B, G9a/KMT1C and the closely related protein GLP/KMT1D, SETDB1/ KMT1E and CLL8/KMT1F, of which G9a and SETDB1 may function as oncogenes. The KMT1 family of proteins methylate H3K9, which induces gene silencing and heterochromatin formation. G9a is overexpressed in some tumours, including leukaemia and lung cancer, and may suppress TSGs or regulate p53 activity by methylation Huang et al., 2010) . SETDB1 is recurrently amplified in melanoma and cooperates with oncogenic BRAF in accelerating oncogenesis, possibly by deregulation of HOX genes (Ceol et al., 2011) . In contrast to the KMT1 family, other H3K9 methyltransferases such as RIZ1/KMT8, SMYD4 and EHMT1 are inactivated by mutations, suggesting that these function as TSGs. KMT8/RIZ1 is commonly inactivated in breast, liver and colon cancers. KMT8 can be silenced by promoter hyper-methylation; is located on the frequently deleted 1p36 chromosomal locus; and is subject to PR domain-targeting loss-offunction mutations (He et al., 1998; Chadwick et al., 2000; Steele-Perkins et al., 2001 ). Kmt8-knockout mice develop tumours of a broad spectrum at a high incidence (Steele-Perkins et al., 2001). Finally, homozygous deletions in poorly characterized SMYD4 and EHMT1 were found in medulloblastoma (Northcott et al., 2009) .
The MLL proteins (MLL1-5/KMT2A-E) are H3K4 methyltransferases and are considered to be transcriptional activators. Translocations of MLL occur in 10% of AML and 70% of infant leukaemias, and are associated with poor clinical outcome (Marschalek, 2011) . Seventy-one MLL fusion partners have been identified that behave as dominantly acting oncogenes that promote leukaemogenesis. Many of these require the H3K79 methyltransferase DOT1L/KMT4 for leukemic cell growth by enhancing the expression of the HOX genes HOXA9 and MEIS1, which are important for MLL-dependent leukaemogenesis (Ayton and Cleary, 2003; Bernt et al., 2011; Daigle et al., 2011; Marschalek, 2011; Nguyen et al., 2011) . Recently, recurrent inactivating mutations in MLL2 and MLL3 were detected in non-Hodgkin's lymphoma, renal carcinoma and medulloblastoma, suggesting that MLL2 and 3 can also function as tumour suppressors (Dalgliesh et al., 2010; Morin et al., 2011; Parsons et al., 2011) . Given that MLL2 and 3 reside in complexes that are essential for normal development and differentiation, it was proposed that inactivation of MLL2 and 3 might lead to aberrant cellular proliferation (Parsons et al., 2011) .
The KMT3-family members function as transcriptional activators by methylating H3K36 and consist of SETD2/KMT3A, NSD1/KMT3B and SMYD2/ KMT3C, of which SETD2 and NSD1 are deregulated in cancer. Truncating mutations in SETD2 were recently detected in clear cell renal carcinoma (Dalgliesh et al., 2010; Varela et al., 2011) . Deficiency of NSD1 leads to Sotos syndrome, an overgrowth condition that leads to developmental defects and predisposes to cancer development (Rahman, 2005) . NSD1 is also frequently fused to NUP98 in AML and induces leukaemia by enforcing the expression of the proto-oncogenes HOXA7, HOXA9, HOXA10 and MEIS1 (Jaju et al., 2001) . Finally, NSD1 promoter hyper-methylation was detected in many neuroblastoma and gliomas, and this could predict poor outcome in high-risk neuroblastoma (Berdasco et al., 2009) . EZH2/KMT6 is an H3K27 methyltransferase, and together with SUZ12 and EED forms the core components of the PRC2 repressor complex, which frequently induces aberrant gene repression in cancer. First, PRC2-enriched genes frequently acquire aberrant promoter methylation, possibly by recruitment of DNMTs or HDACs by EZH2 and EED (van der Vlag and Otte, 1999; Vire et al., 2006; McGarvey et al., 2008) . Second, EZH2 can associate with the melanoma antigen PRAME, which together appear to have a role in inhibiting retinoic acid signalling, which is known to suppress tumourigenesis (Epping et al., 2005) . EZH2 is overexpressed in many cancers (Chase and Cross, 2011) . EZH2 overexpression is associated with aggressive and metastatic disease in both prostate and breast cancer, and is associated with poor clinical outcome in breast carcinoma (Kleer et al., 2003) . Recently, a gain-offunction mutation in the SET domain of EZH2, resulting in enhanced H3K27 trimethylation, was identified in non-Hodgkin's lymphoma (Morin et al., 2010; Yap et al., 2011) . Besides EZH2, the other PRC2 component, SUZ12, can be translocated in endometrial cancer (Koontz et al., 2001) .
Inhibitors against some of the pro-oncogenic KMTs have been developed (Figure 3) . BIX-01294 and UNC638 are highly selective inhibitors of G9a and GLP, leading to demethylation of H3K9me2 in mouse embryonic stem cells (Kubicek et al., 2007; Chang et al., 2009; Vedadi et al., 2011) . UNC638 inhibited cell viability and growth of breast carcinoma cell lines in association with reduced H3K9 methylation of G9a-regulated genes (Vedadi et al., 2011) . Of all the other H3K9 methyltransferases, only SETDB1 could represent a potential target for therapy of melanoma, perhaps most effectively in combination with a BRAF inhibitor, given the functional cooperation between SETDB1 and BRAF in carcinogenesis. Targeting MLL-translocated leukaemias with DOT1L inhibitors is a promising novel therapeutic strategy. A potent and selective DOT1L inhibitor (EPZ004777) blocked H3K79 methylation and consequent activation of leukaemogenic genes, including HOXA9 and MEIS1, in leukemic cells bearing the MLL translocations (Daigle et al., 2011) . Importantly, this led to selective killing of MLL-rearranged cells and induced survival in a mouse MLL xenograft model. NSD1 and SETD2 can be excluded as drug targets as they appear to function as tumour suppressors. EZH2, SUZ12 and EED can be inhibited by 3-deazaneplanocin, leading to reactivation of PRC2-repressed genes and induction of apoptotic cell death in cancer cell lines (Tan et al., 2007) . However, 3-deazaneplanocin nonspecifically inhibits S-adenosyl-L-methionine-dependent activity of histone methyltransferases and was reported to globally inhibit histone methylation (Tan et al., 2007; Miranda et al., 2009) . Given that PRC2 and HDACs can cooperate in transcriptional repression, 3-deazaneplanocin and HDACis synergized in inducing apoptosis in AML cells in association with enhanced reactivation of PRC2 target genes and in colorectal cancer cells by reactivating a WNT inhibitor, repressed by hypoacetylation and H3K27 trimethylation (Jiang et al., 2008; Fiskus et al., 2009 ).
Lysine demethylases. Lysine demethylases (KDMs) remove methyl groups from (non-) histone proteins and are divided into two classes: lysine residues on the KDM1/ LSD family and the Jumonji-C (JmjC) domain family (KDM2-KDM8). KDM1 family enzymes are FADdependent amine oxidases that only remove mono-and dimethylated lysines, whereas JmjC family enzymes are Fe(II) 2-oxogluterate-dependent enzymes that are also able to remove trimethyl groups (Pedersen and Helin, 2010) . LSD1/KDM1A demethylates H3K4me1/2 and H3K9me1/2, and is required for development and differentiation (Wang et al., 2009b) . LSD1 resides in many protein complexes that have either tumour-promoting or tumour-suppressive activities. Consequently, both high and low LSD1 expression have been linked to carcinogenesis. High LSD1 expression is associated with poor clinical outcome of prostate cancer, aggressive biology of ER-negative breast cancer and poorly differentiated neuroblastoma (Metzger et al., 2005; Kahl et al., 2006; Schulte et al., 2009; Lim et al., 2010) . However, in certain breast cancers LSD1 suppresses metastasis when overexpressed (Wang et al., 2009c) .
The KDM4 family consists of JMJD2A/KDM4A, JMJD2B/KDM4B, JMJD2C/KDM4C and JMJD2D/ KMM4D, and catalyses the demethylation of H3K9me2/3 and H3K36me2/3. A recent study found that the histone kinase JAK2 (see histone kinases) and GASC1, which are co-localized on the 9p24 chromosome band that is frequently amplified in cancer, cooperate to activate MYC (Rui et al., 2010) . Enforced GASC1 Targeting the epigenome for cancer treatment E-J Geutjes et al expression in immortalized mammary epithelial cells leads to transformation, and depletion of GASC1 inhibits the proliferation of oesophageal squamous carcinoma cells harbouring the GASC1 amplification (Cloos et al., 2006; Wissmann et al., 2007; Liu et al., 2009a) . Collectively, these findings suggest a role for GASC1 as an oncogene. The KDM5 family consists of the H3K4me2/3 demethylases JARID1A/KDM5A, JARID1B/KDM5B, JARID1C/KDM5C and JARID1D/KDM5D, and function as transcriptional repressors. JARID1A/KDM5A is commonly fused to NUP98 in AML and prevents the differentiation-associated removal of H3K4me3 at many loci encoding leukaemogenic transcription factors, leading to their activation and consequent induction of leukaemia (Wang et al., 2009a) . JARID1A is also overexpressed in gastric cancer and inactivates many senescence-associated cell-cycle inhibitors, thereby preventing senescence induction . Inactivating mutations in KDM5C/JARID1C have been detected in renal cell carcinoma, often in association with loss of VHL, which is commonly mutated in these tumours and is causal in tumourigenesis (Dalgliesh et al., 2010; Varela et al., 2011) . JARID1C was proposed to cooperate with VHL in promoting the activation of the hypoxia-inducible factor pathway that promotes cell survival and angiogenesis. Knockdown of JARID1C in VHL-deleted renal cell carcinoma cells lead to reactivation of hypoxia-inducible factor-responsive genes and enhanced tumour growth in a xenograft model (Niu et al., 2011) .
KDM6A/UTX and KDM6B/JMJD3 antagonize PcGmediated gene repression by removing H3K27me3. Mutations of UTX have been found in many cancers, most notably lymphoma, renal cell and bladder carcinoma (van Haaften et al., 2009; Dalgliesh et al., 2010; Gui et al., 2011; Varela et al., 2011; Wartman et al., 2011) . Inhibition of Jmjd3 in MEFs results in repression of the aforementioned cell-cycle-inhibitory Ink4a-Arf locus, a known target of the PRC1 complex (see histone ubiquitinases), inducing their immortalization (Agger et al., 2009; Barradas et al., 2009; Wang et al., 2010) .
Of the KDMs, only GASC1 and LSD1 are potential drug targets and inhibitors of these have been found (Figure 4) . Specific polyamine analogues inhibit LSD1, leading to increased H3K4me2 levels and reactivation of silenced TSGs, in conjunction with inhibition of cancer cell growth in cell lines and xenograft models (Huang et al., 2007 (Huang et al., , 2009 . Given that silenced TSGs are often depleted in H3K4me3 and histone acetylation, and acquire aberrant CpG island hyper-methylation, combined use of LSD1 inhibitors and DNMTis or HDACis synergized in TSG reactivation, and inhibited colorectal and breast cancer growth (Huang et al., 2009 . However, although LSD1 inactivation inhibited the xenograft growth of LSD1-overexpressing neuroblastoma cells, it induced tumourigenesis in Drosophila, raising concerns about the effects of LSD1 inhibition on noncancer cells (Schulte et al., 2009; Eliazer et al., 2011) (Wang et al., 2009c) . Inhibitors of the KDM4 family have recently been developed (Hamada et al., 2010) . Dual inactivation of GASC1 by these compounds and JAK2 by JAK2 inhibitors (see histone kinases) may be useful in the treatment of lymphomas that have amplified 9p24 as their combined inhibition by RNA interference cooperated in killing these lymphomas (Rui et al., 2010) .
Arginine methyltransferases. Arginine methyltransferases add methyl groups to histone arginine residues and, similar to lysine methylation, the outcomes of these modifications depend on the arginine residue involved. Currently, there is only little evidence that arginine methyltransferases are deregulated in cancer, although they interact with pro-oncogenic proteins (Bedford and Clarke, 2009 ).
Histone kinases. Many histone residues are phosphorylated by kinases, including AKT, JAK2 and PIM1, which have well-established roles in cancer development (Baek, 2011) . Given that these kinases regulate many other key signalling pathways, the contribution of their histone kinase activity to tumourigenesis remains to be determined. We will therefore restrict our discussion to JAK2 for it has a clear role in chromatin signalling and can be targeted in cancer therapy. JAK2 initiates signalling cascades involved in the cell cycle and apoptosis. However, JAK2 also phosphorylates H3Y41, leading to exclusion of heterochromatin protein-1a from the chromatin, thereby activating the haematopoietic oncogene LMO2 (Dawson et al., 2009) . Using a similar mechanism, JAK2 also cooperates with GASC1 in the activation of MYC in leukaemias (see also histone demethylases) (Rui et al., 2010) . JAK2-mediated chromatin signalling appears to be critical for embryonic stem cell self-renewal, a process, which could contribute to the oncogenesis of myeloproliferative diseases, given that these are clonal blood stem cell disorders (Griffiths et al., 2011) . JAK2 gain-of-function mutations (JAK2V617F) are present in 50% of human myeloproliferative diseases and are Targeting the epigenome for cancer treatment E-J Geutjes et al causal in the pathogenesis (Kilpivaara and Levine, 2008) . Several JAK2 inhibitors are in clinical development ( Figure 5 and Table 2 ). As much as half of all patients with myeloproliferative diseases, unselected for JAK2 mutations, responded to treatment with small molecules targeting JAK1/2 in phase-1-2 clinical trials (Verstovsek et al., 2010; Pardanani et al., 2011) .
Histone-ubiquitinating and -de-ubiquitinating enzymes.
Mono-ubiquitination of histones H2A and H2B has important transcriptional consequences. Whereas H2B ubiquitination is mostly associated with transcriptional activation and elongation, H2A ubiquitination is associated with gene repression. H2B ubiquitination is catalysed by BRE1/RNF20 and H2A ubiquitination is catalysed by another PcG complex called PRC1 consisting of the ubiquitin ligase RING1B/RNF2 and BMI1, which enhances the catalytic activity of RING1B. BMI1 may function as an oncogene as it is amplified in B-cell lymphoma (Bea et al., 2001; RubioMoscardo et al., 2005) , and Bmi1 cooperates with cMyc in enhancing tumour aggressiveness and counteracts cMyc-induced apoptosis by repressing the Ink4a-Arf locus (van Lohuizen et al., 1991; Jacobs et al., 1999) . Recently, it was shown that, besides BRE1, the tumour suppressor BRCA1 also ubiquitinates H2A, but specifically at DNA satellite repeats. Loss of BRCA1 induced H2A de-ubiquitination accompanied by de-repression of satellite DNA, leading to genomic instability . Ubiquitin ligases are antagonized by de-ubiquitynating enzymes (DUBs), which remove ubiquitin moieties from protein substrates. There are multiple DUBs targeting histones in a gene-specific manner. De-ubiquitination of H2A by USP16 is important for normal cell-cycle progression and regulation of HOX genes, whereas 2A-DUB-mediated H2A de-ubiquitination controls androgen receptor-dependent gene activation (Joo et al., 2007; Zhu et al., 2007) . Deubiquitination of H2B by USP22/UBP8 is required for SAGA complex-mediated transcriptional activation, whereas the Drosophila H2B DUB USP36 is important for stem cell maintenance (Henry et al., 2003; Buszczak et al., 2009) . Drosophila USP7-GMPS specifically targets H2B for deubiquitination in polycomb mediated gene regulation and ecdysone pathway (van der Knaap et al., 2005; van der Knaap et al., 2010) . USP3 is an H2A and H2B de-ubiquitylase that is involved in the DNA-damage response (Nicassio et al., 2007) .
Nucleosome-remodelling enzymes
Nucleosomes are dynamically repositioned to ensure DNA replication, DNA repair and transcription (Clapier and Cairns, 2009) . Nucleosome occupancy induces chromatin condensation, which not only occludes the transcription factor-binding sites, but also impedes the progress of RNA and DNA polymerases. Specific complexes that contain ATPase activity organize nucleosomes by ejecting, reconfiguring or moving nucleosomes to alternative positions along the DNA. ATP-dependent chromatin remodellers can be subdivided into four classes: SWI/SNF, ISWI, CHD and INO80. Each family shares similar ATPase subunits and core members, but has a different composition of unique subunits. The non-ATPase subunits are required for recognition of DNA and histone modifications, regulation of ATPase activity, and interaction with other chromatin-binding proteins or transcription factors.
SWI/SNF stands out as the most frequently deregulated nucleosome-remodelling complex in cancer (Wilson and Roberts, 2011) . There are two SWI/SNF complexes, named as BAF (BRG1 or BrahmaAssociated Factors) and PBAF (Polybromo-associated BAF complex), which contain one of the two mutually exclusive ATPases BRM or BRG1, and the core subunits SNF5/BAF47, BAF155 and BAF170 (Reisman et al., 2009) . The variant subunits may direct the SWI/ SNF complexes to specific loci and these include ARID1A/BAF250, which is only found in the BAF complexes, and PB1/BAF180, ARID2/BAF200 and BRD7, which specifically reside in the PBAF complexes. The SWI/SNF complexes usually promote transcriptional activation and regulate many processes such as cell-cycle progression, differentiation and DNA repair (Reisman et al., 2009) . SNF5, ARID1A, ARID2, PB1, BRG1 and BRM are deleted, mutated or silenced in many different tumours at a high frequency, showing that SWI/SNF is an important tumour-suppressor complex (Table 1) . SWI/SNF can induce tumourigenesis by many mechanisms and these are likely to be cell typedependent, given that many subunits are tissue specifically expressed (Wilson and Roberts, 2011) . This could also explain the distinct range of cancers associated with the inactivation of each subunit. SNF5 is frequently homozygously deleted or mutated in rhabdoid tumours, which are very aggressive childhood cancers (Versteege et al., 1998) . In addition, one allele of SNF5 can be deleted whereas the other allele is silenced by promoter methylation (Versteege et al., 1998; Rousseau-Merck et al., 1999; Biegel et al., 2000b Biegel et al., , 2002 Biegel and Pollack, 2004) . SNF5 is also heterozygously deleted in Targeting the epigenome for cancer treatment E-J Geutjes et al the chronic and acute phases of chronic myeloid leukaemia (Grand et al., 1999) , and is mutated in Hodgkin's lymphoma (Yuge et al., 2000) . Genetic ablation of Snf5 in the mouse recapitulates the incidence and phenotype of tumours seen in humans (KlochendlerYeivin et al., 2000; Roberts et al., 2000 Roberts et al., , 2002 . Both BRG1 and BRM show high degree of loss-ofheterozygosity in non-small-lung carcinoma and BRM is epigenetically silenced in various cell lines. BRG1 and BRM expression is simultaneously lost in 30-40% of lung cancer cell lines and 15-20% of non-small-cell lung carcinoma (Reisman et al., 2003; Fukuoka et al., 2004; Rodriguez-Nieto et al., 2011) . Knockout of either Brg1 or Brm leads to cancer development in mice with Brg1 functioning as a haploinsufficient TSG (Bultman et al., 2000 (Bultman et al., , 2008 Glaros et al., 2008) . Recently, highthroughput sequencing identified highly recurrent mutations in ARID1A, ARID2 and PB1 in many tumours. Loss-of-function mutations in ARID1A were detected in approximately 50% of ovarian clear cell carcinomas, 30% of endometrioid carcinomas and 12% of bladder cancers Wiegand et al., 2010; Gui et al., 2011) . PB1 is mutated in 41% of clear cell renal carcinomas and ARID2 is mutated in 18% of hepatocellular carcinomas Varela et al., 2011) . Besides SWI/SNF, the CHD-family member CHD5 is also frequently inactivated in cancer. Inactivation of CHD5 by homozygous deletions and promoter hypermethylation has been detected in gliomas, neuroblastomas, colorectal and breast cancers, and CHD5 ablation in the mouse enhances proliferation and blocks senescence through repression of the Ink4a-Arf locus (Bagchi et al., 2007; Fujita et al., 2008; Leary et al., 2008; Mulero-Navarro and Esteller, 2008) .
Strategies that restore the function of SWI/SNF and CHD5 are likely to be of therapeutic benefit, given the importance of these complexes in cancer. BRG1, BRM and CHD5 can be inactivated by epimutations, raising the possibility that epigenetic therapy could also be used to revert these epimutations. Indeed, HDACis can restore the expression of epimutated BRM and DNMTi can reactivate silenced CHD5 in cancer cells (Yamamichi et al., 2005; Glaros et al., 2007; Mulero-Navarro and Esteller, 2008) .
Future directions for epigenetic therapy
We have provided an overview of the epigenetic enzymes that are deregulated in cancer and the feasibility to target these for cancer therapy. A bewildering amount of epigenetic enzymes, involved in multiple layers of epigenetic regulation, including DNA (hydroxyl)-methylation, histone modification and nucleosome remodelling, are deregulated at high frequency in many cancers (Table 1) . The clinical successes of DNMTis and HDACis clearly validate the usefulness of epigenetic therapy in cancer treatment, and other epigenetic enzymes such as MYST3, AIB1, SETDB1, GASC1 and BMI1 are potential drug targets in cancer therapy. While inhibitors of DNMTs, HDACs, G9a/GLP, LSD1 and EZH2 restore aberrantly silenced signalling pathways, inhibitors of JAK2, DOT1L and BRDs function by blocking those that are aberrantly hyper-activated in cancer. The latter are highly selective inhibitors that only appear to kill cancer cells with the deregulated epigenetic target, possibly because the resultant epigenetic changes may have addicted these cells to altered signalling pathways (Filippakopoulos et al., 2010; Verstovsek et al., 2010; Daigle et al., 2011) . Thus, tumours should be classified according to the deregulation of their epigenetic targets to allow effective epigenetic therapy. This becomes even more crucial with the recognition that some epigenetic enzymes such as MLL2/3 and LSD1 can function both as tumour suppressors and oncoproteins. Molecular classification of tumours could also guide treatment with broad-acting epigenetic drugs. DNMTis could be particularly useful in treating the subset of colorectal, brain and breast tumours that have a high degree of CpG island promoter hyper-methylation (Toyota et al., 1999; Noushmehr et al., 2010; Fang et al., 2011) , which is now being clinically tested in colorectal cancer patients.
Although DNMTis and HDACis are clinically effective in some haematological malignancies, clinical proof of concept for solid tumours remains to be established. The clinical failures of current DNMTis and HDACis are ascribed to dosing-related issues, drug delivery problems, intrinsic resistance and the fact that these agents have pleiotropic effects. The incorporation of DNMTis is DNA replication-dependent, meaning that slowly proliferating cancer cells could survive DNMTi treatment (Issa and Kantarjian, 2009 ). Responsiveness to DNMTis and HDACis is critically determined by pharmacogenetic factors that affect the uptake and metabolism of these agents (Voso et al., 2009; Geutjes et al., 2011) . Such issues could potentially be avoided with the new DNMTis as they do not require metabolic activation or DNA replication for their incorporation. Finally, global hypo-methylation and non-specific HDAC inhibition activate both tumourpromoting and tumour-inhibiting genes in a cell contextdependent manner (Gius et al., 2004; Piekarz and Bates, 2009 ). For example, oncogenes such as MYC, EGFR and E2F1 were induced in liver cancer cell lines resistant to the DNMTi zebularine, but not in those sensitive to zebularine in which TSGs were reactivated (Andersen et al., 2010) . Although HDAC3 is overexpressed in many tumours, liver-specific inactivation of Hdac3 in mice culminates in hepatocellular carcinoma (Bhaskara et al., 2010) . It has been proposed that the clinical inefficacy of DNMTis and HDACis in solid tumours is caused by these agents promoting survival rather than apoptosis in solid tumours as they have more (epi-) mutations and perhaps also more dysfunctional apoptotic pathways than haematological malignancies (Nowell, 2002; Piekarz and Bates, 2009) . In support of this, some solid tumours are sensitive to the combination of DNMTis or HDACis with apoptosisinducing therapy, which together more effectively trigger pro-apoptotic signalling pathways (reviewed by Bolden et al., 2006; Boumber and Issa, 2011) . Thus, particularly in solid tumours, clinical success with DNMTis and HDACis, and possibly other broadly acting agents, may require combinations with apoptosisinducing therapy.
Another approach would be to develop novel agents that selectively reactivate epimutated TSGs while avoiding global gene activation and off-target effects. However, for most silenced TSGs we have not identified the enzymes involved and consequently do not know the relevant drug targets. Loss-of-function genetic screens with libraries that target chromatin modifiers could be useful in identifying such enzymes. RNA interference screens have identified the mediators of epigenetic silencing of RASSF1A and the death receptor FAS (Gazin et al., 2007; Palakurthy et al., 2009) . Some of these were constituents of repressor complexes such as PcG. Targeting the subunits that are specific to these complexes might lead to reactivation of silenced TSGs while avoiding global effects, perhaps translating into improved clinical efficacy.
The many epimutated TSGs and deregulated epigenetic enzymes in cancer clearly demonstrate that aberrant epigenetic regulation is a significant contributor to carcinogenesis. The reversibility of epigenetic abnormalities makes the epigenetic enzymes responsible for establishing these modifications good targets for therapeutic intervention. Molecular classification of tumours should guide treatment with epigenetic therapy and can be combined with other anticancer agents to enhance clinical efficacy and to overcome or prevent drug resistance. The recent findings indicating that many epigenetic enzymes are mutated in cancer also suggest that cancer genome resequencing may become helpful to guide the choice of epigenetic therapy.
